Txa127
Txa127 is a protein pharmaceutical. It is currently being investigated in clinical studies. It is known to target type-2 angiotensin II receptor and proto-oncogene Mas.
Download report
Favorite
COVID-19
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
32 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | U07.1 | 1 | 4 | 1 | — | 2 | 6 | |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | 1 | 2 | 1 | — | — | 2 |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | 1 | 2 | 1 | — | — | 2 |
| Sars-cov-2 | D000086402 | — | 1 | 1 | — | — | 1 | ||
| Coronavirus | D017934 | — | 1 | 1 | — | — | 1 | ||
| Disease | D004194 | EFO_0000408 | R69 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hematologic neoplasms | D019337 | — | 3 | — | — | — | 3 | ||
| Cognitive dysfunction | D060825 | G31.84 | — | 2 | — | — | — | 2 | |
| Heart failure | D006333 | EFO_0003144 | I50 | 1 | 2 | — | — | — | 2 |
| Non-hodgkin lymphoma | D008228 | C85.9 | 1 | 1 | — | — | — | 2 | |
| Hodgkin disease | D006689 | C81 | 1 | 1 | — | — | — | 2 | |
| Coronary artery bypass | D001026 | EFO_0003776 | — | 1 | — | — | — | 1 | |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | — | 1 | — | — | — | 1 |
| Sarcoma | D012509 | — | 1 | — | — | — | 1 | ||
| Osteosarcoma | D012516 | — | 1 | — | — | — | 1 | ||
| Bone neoplasms | D001859 | EFO_0003820 | D16 | — | 1 | — | — | — | 1 |
Show 6 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 5 | — | — | — | — | 5 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 3 | — | — | — | — | 3 |
| Myelodysplastic syndromes | D009190 | D46 | 2 | — | — | — | — | 2 | |
| Peripheral arterial disease | D058729 | EFO_0004265 | 1 | — | — | — | — | 1 | |
| Insulin resistance | D007333 | EFO_0002614 | 1 | — | — | — | — | 1 | |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | 1 | — | — | — | — | 1 |
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | 1 | — | — | — | — | 1 |
| Pure autonomic failure | D054970 | 1 | — | — | — | — | 1 | ||
| Shy-drager syndrome | D012791 | EFO_1001050 | 1 | — | — | — | — | 1 | |
| Essential hypertension | D000075222 | I10 | 1 | — | — | — | — | 1 |
Show 8 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renin-angiotensin system | D012084 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TXA127 |
| INN | — |
| Description | Ile(5)-angiotensin II (1-7) is an angiotensin compound consisting of the linear heptapeptide sequence L-Asp-L-Arg-L-Val-L-Tyr-L-Ile-L-His-L-Pro. It has a role as a vasodilator agent. It is a tautomer of an Ile(5)-angiotensin II (1-7) dizwitterion. |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 51833-78-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3545347 |
| ChEBI ID | 55438 |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | — |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 39 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
43 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more